Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting the multifaceted BRAF in cancer: New directions.

Oncotarget - 16 Jul 2024

Toye Eamon, Chehrazi-Raffle Alexander, Hwang Justin, Antonarakis Emmanuel S

Abstract excerpt

Activating mutations in the mitogen-activated protein kinase (MAPK) pathway represent driver alterations governing tumorigenesis, metastasis, and therapy resistance. MAPK activation predominantly occurs through genomic alterations in RAS and BRAF. BRAF is an effector kinase that functions downstream of RAS and propagates this oncogenic activity through MEK and ERK. Across cancers, BRAF alterations include...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRAF gene
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 39018217
DOI: 10.18632/oncotarget.28612
PMCID: PMC11254297

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting the multifaceted BRAF in cancer: New directions.PMID 39018217Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

Defining and Targeting BRAF Mutations in Solid Tumors.Semantic proximity Read ↗

BRAF: A Two-Faced Janus.Semantic proximity Read ↗

Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid TumorsSemantic proximity Read ↗

Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer AnalysisSemantic proximity Read ↗

Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer typesSemantic proximity Read ↗

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.Semantic proximity Read ↗

BRAF Mutations: Oncogenic Drivers in Solid TumorsSemantic proximity Read ↗

BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical ApplicationsSemantic proximity Read ↗

[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].Semantic proximity Read ↗

BRAF as a target for cancer therapy.Semantic proximity Read ↗

BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.